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Background: Functional immobility can cause functional disability in patients with
schizophrenia and has been linked to prognosis and mortality. Although depression
might be a barrier for physical activity engagement, scarce data are present on the
relationship between depression and functional mobility (FM) in schizophrenia. Thus, we
aimed to investigate the associations among FM, depression, and other clinical correlates
in individuals with schizophrenia.
Methods: FM was evaluated by the pedometer-assessed daily steps and Timed Up-and-
Go (TUG) test in the daily-living and clinical settings, respectively. Psychiatric symptoms
were assessed using the Beck Depression Inventory, Brief Psychiatric Rating Scale
(BPRS), and State-Trait Anxiety Inventory. Cognitive function was evaluated using the
Sternberg Working Memory (SWM) Task. Multiple regression analyses were performed to
identify predictive factors associated with FM, with adjustment for relevant covariates.
Results: Sixty patients were enrolled in this study. Depression was the most consistent
explanatory variable for both pedometer (b = −0.34, p = 0.011) and TUG time (b = 0.32,
p = 0.018). Additionally, SWM accuracy (b = −0.29, p = 0.018), BPRS-Withdrawal (b =
0.19, p = 0.139), and fasting blood sugar (b = 0.34, p = 0.008) were associated with TUG
time. However, psychotic symptoms and anxiety were not associated with pedometer
and TUG.
Conclusions: We identified an association between depression and FM after adjusting
for other disorder-related correlates in schizophrenia. Since the intervention goal is
functional recovery, improving FM by treating depression may have considerable
therapeutic value.
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Although psychotic symptoms are a key feature of schizophrenia,
the most costly problem in this condition is significant functional
disability (1). One of the main causes of functional disability in
patients with schizophrenia is impairment in functional mobility
(FM) (2). FM is the ability to move from one place to another
independently in the environment (3) and requires complex
physical processes such as walking, transferring, and turning (4).
Because FM enables functional living, including the ability to
perform activities of daily living (3), it is necessary to focus on
FM in schizophrenia.
Multiple factors may contribute to the FM impairments in
patients with schizophrenia, including chronic medical conditions
(e.g., diabetes, obesity), sedentary behavior, physical inactivity, or
side effects of antipsychotic drugs (5–9). There is also evidence
showing that FM predicts overall health decline and disability in
activities of daily living (10). Based on these studies, FM can be
directly linked to the prognosis and mortality of schizophrenia in
the long term. Therefore, in addition to examining the various
health factors that may affect FM, it is also important to explore
other factors that may affect FM.
One such factor is psychiatric symptoms. A cross-sectional study
focusing on psychiatric symptoms found that positive psychotic
symptoms were not associated with everyday functioning in
patients with schizophrenia (11). In addition, some researchers
have shown that the relationship between positive symptoms and
FM is not clear (5, 12). These findings imply that patients may
experience persistent disability in multiple functional domains even
after remission of psychotic symptoms (13). Therefore, it is necessary
to examine the effects of other psychiatric symptoms, such as
depression, on FM in patients with schizophrenia.
Depressive symptoms in schizophrenia are not only prevalent in
the prodromal active and remission phases, but also are militating
against long-term recovery (14). Depression results in perceived
functional disability and increases the need to utilize healthcare
services (15). Furthermore, depression has been found to predict
FM limitations (16), and Hirvensalo et al. (17) proposed that
depression and FM may progress simultaneously and partially
share etiology. Such findings suggest that depression plays an
important role in the FM impairments in schizophrenia.
Stubbs et al. (18) have suggested that depressive symptoms
might be a barrier for engaging in vigorous physical activity;
however, there is still a lack of data on the relationship between
depressionandFMinschizophrenia.Apedometeroraccelerometer
can objectively measure physical activity-related mobility without
interfering with the normal patterns of life (19, 20). These
measurements have previously been applied to assess the mobility
level related to physical activity in individuals with mobility
limitations (20, 21).
However, such mobility-related activity measurements are
limited in their ability to assess the complex physical processes of
FM. Therefore, the Timed Up-and-Go (TUG) test (22), a simple,
practical, and widely used clinical performance-based test, is often
employed to measure FM (4). The psychometric properties of the
TUG test have high inter-rater and test-retest reliability (22).
Despite its apparent simplicity, the TUG test has the advantage ofFrontiers in Psychiatry | www.frontiersin.org 2reflectingmultiple components ofFM, and thus canhelppredict the
overall functional level of the patient’s daily life (4). To our
knowledge, only one prior study has administered the TUG test
to patients with schizophrenia (5). In that study, the FMmeasured
by the TUG test was associated with negative symptoms and
neurocognition in 46 older adults with schizophrenia, but
depressive symptoms were not measured. As such, studies
evaluating the relationship between FM, as assessed with the both
a pedometer and the TUG test, and depression in schizophrenia
are needed.
In the present study, we aimed to investigate the relationships
among FM, depression, and other clinical correlates in
individuals with schizophrenia. FM was assessed with both a
pedometer and the TUG test. The clinical correlates included
psychiatric symptoms (depression, anxiety, and psychotic
symptoms), psychological variables (quality of life, self-esteem),
cognitive function (working memory), and other related clinical
factors (diabetes, obesity, and antipsychotic drugs). We
hypothesized that lower FM would be associated with higher
depressive symptoms, regardless of other clinical correlates, in
patients with schizophrenia.METHODS
Participants and Design
A cross-sectional design was used to examine the hypothesis. All
procedures were approved by the Investigational Review Board
of Severance Mental Health Hospital (IRB#: YJI130702). All
participants provided written informed consent.
Patients aged 18 to 60 with a primary diagnosis of schizophrenia
or schizoaffective disorder were recruited via posters placed in local
hospitals with psychiatric units and community mental health
centers, and via advertisements in local newspapers. Some patients
were also referred by other local health professionals. Participants
were included if they had a diagnosis of schizophrenia or
schizoaffective disorder according to the Diagnostic and Statistical
Manual for Mental Disorders, 4th Edition, Text Revision. Face-to-
face diagnostic interviews were conducted by a psychiatric/mental
health nurse and a board-certified psychiatrist who reviewed the
history, symptoms, and psychosocial function of each patient using
all available sources of information, in accordance with DSM-IV-TR
criteria. All participants were required to be on a stable dose and
dosing regimen of antipsychotics for at least 4 weeks prior to
assessment. Participants were excluded if they had participated in
any exercise program within 3 months of study onset or displayed
evidence of significant cardiovascular, neuromuscular, endocrine, or
other somatic/substance use disorders that would prevent safe
participation. Five of the recruited participants failed to meet the
initial eligibility criteria, and thus, a total of 60 patients were included
in the final analysis.
Sociodemographic and Clinical
Information
Evaluationof all variables for eachparticipantwasperformedon the
same day within 2 weeks from screening date. Sociodemographic
information (age, sex, years of education, duration of illness) andAugust 2020 | Volume 11 | Article 854
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antipsychotics, fasting blood sugar [FBS], body mass index)
were collected.
Antipsychotic Dosing
To yield antipsychotic dosing, the prescribed daily dose (PDD) in
milligrams was divided by the defined daily dose (DDD) to
calculate a PDD : DDD ratio. DDD is defined as the assumed
average daily maintenance dose for a drug used for its main
indication in adults (23).
Psychiatric Symptoms
Psychiatric symptoms were determined via interviews and self-
report questionnaires. Outcome measures for psychiatric
symptoms included the Beck Depression Inventory (BDI),
Brief Psychiatric Rating Scale (BPRS), and State and Trait
Anxiety Inventory (STAI).
Beck Depression Inventory (BDI)
The BDI was used to assess depressive symptoms (24). The BDI
is a 21-item self-report inventory that asks participants to choose
the one statement that best describes their feelings during the
past 2 weeks.
Brief Psychiatric Rating Scale (BPRS)
The BPRS is an 18-item, semi-structured introductory interview
that is completed by the interviewer (25). Each item is rated on a
scale from 0 to 6. Scores between 15 and 30 indicate minor
symptoms, while those above 30 indicate major symptoms. The
BPRS has following five subscales: Thought (items - grandiosity,
hallucinations, unusual thought content, and conceptual
disorganization), Withdrawal (items - disorientation, blunted
affect, emotional withdrawal, and motor retardation), Anxiety
and Depression (items—somatic concern, anxiety, depression,
and guilt), Paranoid (items—hostility, suspicion, and
uncooperativeness), and Excitement (items—tension, excitement,
and mannerisms and posturing) (26).
State-Trait Anxiety Inventory (STAI)
The STAI is a self-rated instrument that contains two 20-item
subscales for the measurement of anxiety (27). One scale
measures state anxiety, while the other measures trait anxiety.
Psychological Variables
Psychological variables included the Rosenberg Self-Esteem Scale
(RSES) and World Health Organization Quality of Life
Scale (QOL).
Rosenberg Self-Esteem Scale (RSES)
RSES is a 4-point scale consisting of 10 questions, 5 positive and
5 negative self-esteem. The higher the score, the higher the
degree of positive self-esteem (28).
2.4.2 World Health Organization Quality of Life Scale
Abbreviated Version (WHOQOL-BREF)
The World Health Quality Assessment Instrument-100 (29)
was revised by Min et al. (30) to develop the Korean version ofFrontiers in Psychiatry | www.frontiersin.org 3WHOQOL-BREF. This is composed of a total of 24 items on the
5-point scale and higher score means higher quality of life.
Cognitive Function
Sternberg Working Memory (SWM) Task
The classic Sternberg Working Memory (SWM) task (31) was
administered using Inquisit 5.0.13.0 (Millisecond Software, LLC,
Seattle,WA,USA). Each trial of the task consisted of a set of two to
five white digits presented in a sequence (1200 ms each). A yellow
probe digit appeared 2500 ms after the last digit (maintenance
period), at which point participants were required to press an
appropriate button indicating whether the digit had been present
in the previously displayed sequence. Participants were provided
with visual feedback regarding the accuracy of their responses.
Task sessions were divided into equally distributed “in” (probe
present in the memory sequence) and “out” (probe not present in




A pedometer is an inexpensive and easy-to-use device that
measures real-time physical activity by counting an individual’s
steps during daily life (19). Typical physical activity, such as
walking, reflects the level of daily FM well (20), and walking has
been shown to improve various aspects of FM (20). In brief, as
walking is the most primary mode of physical activity, counting
steps with a pedometer is useful for quantifying the level of FM
(20). In the present study, The Yamax digiwalker SW-200 (Yamax
Corporation, Tokyo, Japan) were used one time for two
consecutive days. In order not to interfere with the daily life of
research participants, we did not have any restrictions except to
wear a pedometer in the waist.
Timed Up and Go (TUG) Test
In contrast to the pedometer, which mainly measures FM during
daily living, the TUG test is a performance-based FM test that
requires an individual to perform complex physical activities in a
clinical setting (4, 32). The TUG test includes turning, transfers
from sitting, and walking, and requires more functional
movement (4). This study used the TUG test described by
Podsiadlo and Richardson (22). The participants were asked to
perform the TUG test at their own pace in a well-lit environment.
For the TUG test, the participants were seated and were allowed
to use the arms of the chair to help them stand up. During the
test, the participants were observed and timed during all the time
they stood up from a seated position in an arm chair, walked 3 m,
turned around, walked back to the chair, and then returned to a
seated position.
Statistical Analysis
Descriptive analyses of the sociodemographic and clinical
variables were performed. Quantitative variables are described
as the mean ± standard deviation and qualitative variables as the
number and percentage. Multiple regression analyses were used
to identify predictive factors associated with FM, withAugust 2020 | Volume 11 | Article 854
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correlation analyses to identify the associated factors, separate
multivariate stepwise analyses were conducted, with either the
TUG test or pedometer variable as the dependent variable, for
FM. All analyses were performed using SPSS version 18.0 (SPSS,
Chicago, IL). Statistical significance was set at p < 0.05.RESULTS
Correlation Analysis
Table 1 shows the descriptive statistics and correlations between
the clinical characteristics and FM. The Pearson correlation
coefficients showed that the pedometer values was the mean
number of steps per day, which were significantly positively
correlated with the RSES (p = 0.033) and QOL (p = 0.047) scores,
but significantly negatively correlated with the BPRS-Total (p =
0.038) and BDI (p = 0.011) scores. In addition, the TUG test
times were significantly positively correlated with FBS (p =
0.031), as well as with the BPRS-Withdrawal (p = 0.008), BDI
(p = 0.010), and Trait Anxiety Inventory (p = 0.026) scores;
however, the TUG test times were significantly negatively
correlated with the SWM correct rate (p = 0.011).Frontiers in Psychiatry | www.frontiersin.org 4Multiple Regression Analysis
Multivariate analyses were applied to determine which variables
were closely related to the pedometer values and TUG test times
after adjusting for other clinical correlates. Significantly
associated variables, as determined by the univariate analyses,
were included as independent variables. Separate stepwise
multiple regression analyses for the pedometer and TUG test
variables provided the following models. As shown in Table 2,
after excluding the BPRS-Total, RSES, and QOL scores, the only
significant predictor of the pedometer value was the BDI score,
which accounted for 12% of the variance. According to Table 3,
in the first step, the SWM correct rate, FBS, and BDI score were
significant predictors of changes in the TUG test times,
accounting for 36% of the variance. In the second step, the
introduction of the BPRS-Withdrawal score increased this
to 39%.DISCUSSION
Previous research examining the relationship between FM and
depression in patients with schizophrenia utilized tests that
measured mobility during activities of daily living (e.g.,TABLE 1 | Clinical characteristics and their relationships with functional mobility









Age 38.88 (10.08) −0.15 0.25
Sex (Male) 58.30% −0.25 0.10
Years of education 14.07 (2.96) 0.05 −0.05
Duration of illness 14.68 (10.15) −0.20 0.10




FBS 106.20 (36.39) 0.01 0.30*
BMI 27.44 (5.18) 0.06 0.06
BPRS-Total 42.26 (15.94) −0.28* 0.26
BPRS-Thought 7.04 (3.59) −0.19 0.20
BPRS-Withdrawal 9.17 (4.02) −0.24 0.36**
BPRS-Anxiety 7.91 (3.47) −0.26 0.02
and Depression
BPRS-Paranoid 5.85 (2.95) −0.19 0.14
BPRS-Excitement 4.33 (2.14) −0.26 0.12
BDI 17.61 (11.01) −0.34* 0.36**





















0.63 (0.21)PDD, prescribed daily dose; DDD, defined daily dose; FBS, fasting blood sugar; BMI,
body mass index; BPRS, Brief Psychiatric Rating Scale, BDI, Beck Depression Inventory;
STA, State Anxiety Inventory; TRA, Trait Anxiety Inventory; RSES, Rosenberg Self-Esteem
Scale; QOL, Quality of Life Scale; SWM, Sternberg Working Memory.
*Significant at p < 0.05 (Pearson correlation, two-tailed); **Significant at p < 0.01 (Pearson
correlation, two-tailed).TABLE 2 | Multivariable stepwise regression of the pedometer values (steps/day)













QOL 1.23 0.226August 2020 | Volume 11 |BDI, Beck Depression Inventory; BPRS, Brief Psychiatric Rating Scale; RSES, Rosenberg
Self-Esteem Scale; QOL, Quality of Life Scale.TABLE 3 | Multivariable stepwise regression of Timed Up-and-Go test times





Step 1 BDI 0.40 3.28 0.002 0.36 8.80
(p < 0.001)
FBS 0.39 3.26 0.002
SWM correct rate −0.28 −2.36 0.023
Step 2 BDI 0.32 2.46 0.018 0.39 7.34
(p < 0.001)
FBS 0.34 2.79 0.008
SWM correct rate −0.29 −2.50 0.018
BPRS-Withdrawal 0.19 1.51 0.139BDI, Beck Depression Inventory; FBS, fasting blood sugar; SWM, Sternberg Working
Memory; BPRS, Brief Psychiatric Rating Scale.Article 854
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our knowledge, the present study is the first to investigate the
effects of depression on FM, not only during daily living with a
pedometer, but also in the clinical setting using the TUG test.
Additionally, we examined the effects of other disorder-related
correlates on FM, including psychiatric symptoms, cognitive
function, psychological status, and health-related variables. The
results demonstrate that depression is the best explanatory
variable for both the pedometer and TUG test values. Further,
working memory and FBS were associated with the TUG test.
The present findings suggest that depression may have the
most consistent influence on FM, regardless of how FM is
measured, in individuals with schizophrenia. However, it is
unclear what mechanisms may underlie the effects of depression
on FM. Depression can affect FM owing to a combination of
psychological, behavioral, and physiological factors. Patients with
depressive schizophrenia are more likely to have low motivation,
poor self-efficacy, psychomotor retardation, a sedentary lifestyle,
and a low level of volition than are patients with non-depressive
schizophrenia (17, 33, 34). Furthermore, these clinical features
could result in poorer performance of up and go movements or
make such patients hesitant to participate in physical activity (17).
In particular, our findings of significant associations between the
TUG test times and low RSES and QOL scores, which are closely
related to depressive symptoms, suggest that a combination of
diverse components in depression can aggravate FM. Indeed,
depression was found in 34% of older people with manifest FM
limitation, which suggest that both conditions may progress
simultaneously (17). This shared etiology also may interfere with
the functional adaptation inparticular chronic schizophrenia (5, 14,
18). Nevertheless, subsequent studies are needed to reveal the
complex mechanisms underlying their relationship.
Similarly, the neurological mechanisms of depression and FM
in schizophrenia have not been elucidated. However, based on a
study of mainly older adults, the volume of subcortical white
matter hyperintensities (WMHs) increases as depressive
symptoms increase, leading to FM and functional impairments
(35). White matter lesions in individuals with depression are
closely related to smaller caudate and putamen volumes, which
can lead to impairments in movement regulation and
psychomotor retardation, respectively (36, 37). Although the
results are inconsistent across studies, there is some evidence
supporting the presence of cerebral WMHs in patients with
schizophrenia (38). Thus, patients with depressive schizophrenia
can be assumed to have weighted FM limitations. In addition,
WMHs in schizophrenia have been found to be associated with
cognitive function (38), which may partially explain the
relationship we observed between the SWM scores and TUG
test times in this study.
One difference in our findingswas that while the TUG test times
were associated with cognition and depression, the pedometer
values were only associated with depression. This is because the
two measures differ in the process and the setting during the test.
The pedometer ismainly used tomeasuremobility-related physical
activity during daily living, thus motivation is an important factor
(32). In contrast, the TUG test requires the rapid completion ofFrontiers in Psychiatry | www.frontiersin.org 5complex physical maneuvers in an experimental setting (4). In this
clinical performance-based FM test, the individual needs to process
and memorize environmental information while simultaneously
performing physical movements (39, 40). It also requires the
planning and initiation of a series of actions (5, 39, 40). In fact,
using the TUG test, Leutwyler et al. (5) showed that in patients with
schizophrenia, slower processing speed, which represents cognitive
dysfunction, affects FM impairments. Thus, the TUG test is a more
complicated process when compared to pedometer, and in
particular, the transferring and tuning components of the TUG
test might tax cognition (4).
Focusing on FBS, it is well known that patients with
schizophrenia are vulnerable to diabetes, impaired glucose
tolerance, and metabolic syndrome (6), but the association of
these factors with FM is unknown. A recent cohort study by
Åström et al. (41) in the elderly demonstrated that individuals
with impaired glucose regulation and diabetes show reduced FM.
According to Åström et al. (41), insulin resistance can increase
protein degradation and decrease protein synthesis in skeletal
muscle, resulting in poor physical performance. This pathology
further exacerbates glucose regulation because skeletal muscle is
important for glucose uptake. In addition, hyperglycemia-
induced changes in neuronal structure are most likely to
contribute to the myelination of brain, and lead to reduction in
neural transmission (42). Furthermore, Kumar (43) have shown
diabetes is associated with greater total brain atrophy and poor
motor function, independent of depression. Taken together, FBS
should be considered as a significant health related factor that
could affect FM in patient with schizophrenia.
Both TUG test and pedometer are valid and reliable for
quantifying FM that are expected to be useful in individuals
with schizophrenia (22). Since TUG test needs only a stopwatch
and a chair and is easy to understand, it is ideal for patients with
schizophrenia. Also, TUG test reflects complex cognitive
function and physical performance, even with simplicity and
cost-effectiveness (4). Thus it will be useful for intervention or
evaluation to recover functional disability for the patients with
schizophrenia (5). Because sedentary behavior or physical
inactivity, which causes disability, are characteristics seen by
patients with schizophrenia, it is necessary to accurately measure
their FM in daily life. In this respect, the pedometer has the
advantage of being able to overcome the limitations of subjective
self-reports and can easily measure and record the mobility-
related physical activity in real time (19).
To date, interventions for patients with schizophrenia have
focused exclusively on psychotic symptoms such as hallucinations
and delusions, with little attention being paid to depression.
Considering that schizophrenia is one of the most disabling
illnesses (1), a more realistic intervention goal would be for the
patient to recover real-world functioning, thereby allowing for
independent living and social adjustment. Our findings, at least in
part, suggest the possibility that the direct treatment of patients’
depressive symptoms may improve their functional ability and
quality of life by increasing their level of FM.Collectively, our results
support that alleviating depression will have considerable
therapeutic value for patients with schizophrenia.August 2020 | Volume 11 | Article 854
Kim et al. Depression and Mobility in SchizophreniaThere are some limitations in this study. First, although the
TUG test used in this study has been used to assess FM in various
clinical populations, this test has not yet been standardized for
patients with schizophrenia. Second, the structured diagnostic
tools were not used, but diagnostic verification was double-
checked by two psychiatric practitioners. In addition, 30-item
Positive and Negative Syndrome Scale (PANSS), could have
provided more adequate representation of negative symptoms
than BPRS. Third, since the sample size of this study was small
and mainly included patients with chronic schizophrenia, our
findings may not be fully generalizable to all patients with
schizophrenia. Fourth, as the study was cross-sectional, no
causal relationships could be established. Physical difficulties,
like FM limitations, may have made patients feel more depressed.
Lastly, this study did not examine the mechanisms underlying
depression and FM. Nevertheless, this study demonstrated for
the first time that the depression experienced by patients with
schizophrenia may impair FM in both the experimental and
daily-living settings based on robust and practical tests, including
the TUG and pedometer assessments. Follow-up studies should
evaluate the biopsychosocial mechanisms of the link between
depression and FM.CONCLUSIONS
The present study demonstrated a strong association between
depression and FM after considering other clinical correlates in
individuals with schizophrenia. Depressive symptoms were
correlated with FM in both the daily-living and clinical
settings, as measured with a pedometer and the TUG test,
respectively. Additionally, memory and FBS were found to be
partially associated with the TUG test. Because patients’ actual
therapeutic goal is functional recovery, improving FM by
treating depression has significant clinical implications. Further
studies to elucidate the mechanisms underlying the relationshipFrontiers in Psychiatry | www.frontiersin.org 6between depression and FM and appropriate intervention studies
to alleviate depression are needed.DATA AVAILABILITY STATEMENT
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